Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021
View
Metabolism, Alcohol & Toxicity
6
Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021
View
Metabolism, Alcohol & Toxicity
6
Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021
View
Metabolism, Alcohol & Toxicity
6
Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Viral Hepatitis
2
GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021
